Mirum Pharmaceuticals (MIRM) Cash & Equivalents (2018 - 2026)

Mirum Pharmaceuticals' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $324.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 53.39% year-over-year to $324.9 million; the TTM figure through Mar 2026 stood at $324.9 million (up 53.39% YoY), while the FY2025 annual figure was $296.7 million, up 33.08% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $324.9 million, up from $296.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $324.9 million in Q1 2026, with the low at $480000.0 in Q3 2025.
• The 5-year median for Cash & Equivalents is $228.1 million (2025), against an average of $215.6 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 512.81% in 2024, then tumbled 99.78% in 2025.
• Mirum Pharmaceuticals' Cash & Equivalents stood at $128.0 million in 2022, then surged by 123.69% to $286.3 million in 2023, then retreated by 22.14% to $222.9 million in 2024, then jumped by 33.08% to $296.7 million in 2025, then advanced by 9.51% to $324.9 million in 2026.
• Business Quant data shows MIRM's Cash & Equivalents at $324.9 million in Q1 2026, $296.7 million in Q4 2025, and $480000.0 in Q3 2025.